FDA’s CDER un­veils de­tails of re­or­ga­ni­za­tion

7 years ago
Pharma

Ipsen adds cowork­ing to new Boston HQ with Bi­o­Labs part­ner­ship; NYC gets biotech start­up ac­cel­er­a­tor, fund­ed with ...

7 years ago
News Briefing

Post-Bris­tol/My­ers buy­out, the IFM team lines up $31M to tack­le a troi­ka of NL­RP3 tar­gets

7 years ago
Financing

In two PhI­II wins for Al­ler­gan/Mol­e­c­u­lar Part­ners, wet AMD drug shows non-in­fe­ri­or­i­ty to Lu­cen­tis

7 years ago
R&D

Aridis Phar­ma seeks $35M to fight in­fec­tions with im­munother­a­pies — lat­est in an IPO streak

7 years ago
Financing

The Shkre­li rule? FDA is ex­plor­ing whether se­lect­ed reim­por­ta­tion could crip­ple the drug prof­i­teers

7 years ago
Pharma

Af­ter bil­lion-dol­lar drug deal, pa­tient death and tri­al hold crip­ple Mer­sana's shares

7 years ago
R&D

Gilead brings Medicxi’s tiny Gade­ta in­to the cell ther­a­py fold, hunt­ing a way to pick the lock on sol­id tu­mors

7 years ago
R&D
Discovery

Go­ing deep­er in­to the ezce­ma game, No­var­tis or­ches­trates $1.1B deal for a Mor­phoSys/Gala­pa­gos drug

7 years ago
R&D
Pharma

Roche’s IM­pow­er 132 hits on pro­gres­sion-free sur­vival, but Mer­ck re­mains in con­trol — for now — on front­line ...

7 years ago
R&D

UK votes to stay in the EMA post-Brex­it

7 years ago
Pharma

Cel­lec­tar climbs (then sinks) on PhII DL­B­CL da­ta; Vyr­i­ad inks deal with Pfiz­er/Mer­ck KGaA

7 years ago
News Briefing

Armed with $36M A round, Johns Hop­kins spin­out Neu­raly heads to PhI Parkin­son's tri­al

7 years ago
Financing
Startups

J&J joins block­buster HIV com­bo race with new­ly ap­proved 4-in-1 pill

7 years ago
Pharma

By the num­bers: Se­ries A rounds are bust­ing out, plat­forms are in, M&A is down, val­u­a­tions surge and 2018 looks ...

7 years ago
Financing
Deals

Eli Lil­ly, Pfiz­er cel­e­brate a PhI­II suc­cess for their block­buster pain drug con­tender tanezum­ab -- but ques­tions ...

7 years ago
R&D

No­var­tis CEO Vas Narasimhan hits the brakes on US drug price hikes -- right af­ter tap­ping the gas

7 years ago
Pharma

Boom time: Ru­bius, Cri­net­ics find big sup­port in up­sized IPOs to­tal­ing $343M raise

7 years ago
Financing
Startups

An­ti­fun­gal out, can­cer in: Rev­o­lu­tion scores $500M Sanofi deal on first on­col­o­gy pro­gram

7 years ago
Pharma

Pre-rev­enue vac­cine de­vel­op­er CanSi­no lines up at a buzzing HKEX

7 years ago
Financing
China

6 Di­men­sions backs Lyv­gen's $30M B round; No­var­tis hands off glob­al rights to IL-2 drug

7 years ago
News Briefing

On its way to mak­ing Hong Kong his­to­ry, As­cle­tis eyes $457M haul in GIC-backed IPO

7 years ago
Financing
China

Vivek Ra­maswamy strikes again, this time launch­ing a Bei­jing-based biotech play­er with a pipeline

7 years ago
Startups

The next Nim­bus? Head of bil­lion-dol­lar drug pro­gram launch­es HotSpot with $45M A round

7 years ago
Financing
Startups
First page Previous page 1011101210131014101510161017 Next page Last page
A service from the Financial Times